CA2230655C
(en)
*
|
1995-08-30 |
2008-06-17 |
Genzyme Corporation |
Chromatographic purification of adenovirus and aav
|
US20020088014A1
(en)
*
|
1996-05-31 |
2002-07-04 |
Xiangming Fang |
Minimal adenovirus mediated recombinant vaccine
|
CA2258158A1
(fr)
|
1996-07-01 |
1998-01-08 |
Francis Blanche |
Procede de production d'adenovirus recombinants
|
ATE348155T1
(de)
|
1996-11-20 |
2007-01-15 |
Introgen Therapeutics Inc |
Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
US6544769B1
(en)
|
1996-12-13 |
2003-04-08 |
Schering Corporation |
Compostions comprising viruses and methods for concentrating virus preparations
|
US6261823B1
(en)
|
1996-12-13 |
2001-07-17 |
Schering Corporation |
Methods for purifying viruses
|
US6995006B2
(en)
*
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
WO1999021977A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Life Technologies, Inc. |
Recombinational cloning using nucleic acids having recombination sites
|
US7705602B2
(en)
*
|
1997-11-03 |
2010-04-27 |
Midtronics, Inc. |
Automotive vehicle electrical system diagnostic device
|
US20040204381A1
(en)
*
|
1997-11-12 |
2004-10-14 |
Moskal Joseph R |
Detection and treatment of glyco-enzyme-related disease
|
US6899870B1
(en)
*
|
1998-03-11 |
2005-05-31 |
Board Of Regents, The University Of Texas System |
Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
|
HUP0102209A2
(hu)
*
|
1998-04-22 |
2001-09-28 |
Genvec, Inc. |
Eljárás adenovírus hatékony tisztítására
|
WO2000022152A1
(en)
*
|
1998-10-13 |
2000-04-20 |
Avigen, Inc. |
Compositions and methods for producing recombinant adeno-associated virus
|
US7691370B2
(en)
*
|
1998-10-15 |
2010-04-06 |
Canji, Inc. |
Selectivity replicating viral vector
|
US6689600B1
(en)
|
1998-11-16 |
2004-02-10 |
Introgen Therapeutics, Inc. |
Formulation of adenovirus for gene therapy
|
WO2000029024A1
(en)
*
|
1998-11-16 |
2000-05-25 |
Introgen Therapeutics, Inc. |
Formulation of adenovirus for gene therapy
|
US7148035B1
(en)
*
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
US6210922B1
(en)
*
|
1998-11-30 |
2001-04-03 |
National Research Council Of Canada |
Serum free production of recombinant proteins and adenoviral vectors
|
EP1141249A1
(fr)
*
|
1998-12-31 |
2001-10-10 |
Aventis Pharma S.A. |
Methode de separation de particules virales
|
FR2788064B1
(fr)
*
|
1998-12-31 |
2003-01-31 |
Aventis Pharma Sa |
Methode de separation de particules virales
|
DE60029195T2
(de)
|
1999-02-22 |
2007-06-28 |
Transgene S.A. |
Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
|
US6795585B1
(en)
|
1999-07-16 |
2004-09-21 |
Eastman Kodak Company |
Representing digital images in a plurality of image processing states
|
EP1246904A2
(en)
*
|
1999-12-29 |
2002-10-09 |
Genzyme Corporation |
Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants
|
US6168941B1
(en)
*
|
2000-04-07 |
2001-01-02 |
Genvec, Inc. |
Method of producing adenoviral vector stocks
|
WO2001082699A1
(en)
*
|
2000-04-28 |
2001-11-08 |
Zengen, Inc. |
A gene therapy system and method using alpha-msh and its derivatives
|
US6783939B2
(en)
*
|
2000-07-07 |
2004-08-31 |
Alphavax, Inc. |
Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
|
TWI289158B
(en)
*
|
2000-08-10 |
2007-11-01 |
Oncolytics Biotech Inc |
Method of producing infectious reovirus
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US20020064860A1
(en)
*
|
2000-11-29 |
2002-05-30 |
Schering Corporation |
Method for purifying adenoviruses
|
IL157304A0
(en)
|
2001-03-16 |
2004-02-19 |
Oncolytics Biotech Inc |
Method of extracting virus from cell culture
|
US20040146590A1
(en)
*
|
2001-03-22 |
2004-07-29 |
Iadarola Michael J |
Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
|
JP4499990B2
(ja)
*
|
2001-03-27 |
2010-07-14 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcv感染に有用な組成物および方法
|
ES2564553T3
(es)
|
2001-08-08 |
2016-03-23 |
The Trustees Of The University Of Pennsylvania |
Procedimiento para purificar vectores víricos que tienen proteínas que se unen a ácido siálico
|
US20040253210A1
(en)
*
|
2001-08-30 |
2004-12-16 |
Marjorie Robert-Guroff |
Adenovirus type7 vectors
|
JP4790984B2
(ja)
*
|
2001-09-06 |
2011-10-12 |
アルファヴァックス,インコーポレイテッド |
アルファウイルスレプリコンベクター系
|
WO2003039459A2
(en)
*
|
2001-11-05 |
2003-05-15 |
Genvec, Inc. |
Viral vector production methods and compositions
|
JP5322252B2
(ja)
*
|
2001-12-20 |
2013-10-23 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
感染細胞からのポックスウイルスの採取および精製法
|
KR100451308B1
(ko)
*
|
2001-12-28 |
2004-10-06 |
선바이오(주) |
단백질 의약품 정제 방법에서의 바이러스 제거 방법
|
AU2003217413A1
(en)
*
|
2002-02-14 |
2003-09-04 |
Novavax, Inc. |
Method for isolation and purification of expressed gene products in vitro
|
DE60304836T2
(de)
*
|
2002-02-20 |
2006-11-30 |
Merck & Co., Inc. |
Verfahren zur konzentrationsbestimmung von adenoviruspartikeln
|
US20030180936A1
(en)
*
|
2002-03-15 |
2003-09-25 |
Memarzadeh Bahram Eric |
Method for the purification, production and formulation of oncolytic adenoviruses
|
US20030175688A1
(en)
*
|
2002-03-15 |
2003-09-18 |
Rukmini Pennathur-Das |
Method for the purification and production of oncolytic adenoviruses
|
US20030186832A1
(en)
*
|
2002-03-15 |
2003-10-02 |
Unilever Home & Personal Care Usa, Division Of Conopco, Inc. |
Isotropic liquid detergents with improved anti-redeposition
|
CA2478932A1
(en)
*
|
2002-03-29 |
2003-10-16 |
Merck & Co., Inc. |
Large scale methods of producing adenovirus and adenovirus seed stocks
|
BR0309659A
(pt)
|
2002-04-30 |
2005-02-22 |
Oncolytics Biotech Inc |
Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
|
ES2357366T3
(es)
*
|
2002-05-14 |
2011-04-25 |
MERCK SHARP & DOHME CORP. |
Procedimientos de purificación de adenovirus.
|
US20030224354A1
(en)
*
|
2002-05-30 |
2003-12-04 |
Introgen Therapeutics Inc. |
Quantifying viral particles with intrinsic fluorescence
|
EP1371723A1
(en)
*
|
2002-06-12 |
2003-12-17 |
Procorde GmbH |
Process for preparing an adenovirus-containing preparation
|
AU2003253992A1
(en)
*
|
2002-07-18 |
2004-02-09 |
Robert P. Bennett |
Viral vectors containing recombination sites
|
WO2004020971A2
(en)
*
|
2002-08-28 |
2004-03-11 |
Introgen Therapeutics Inc. |
Chromatographic methods for adenovirus purification
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
CA2500727A1
(en)
*
|
2002-10-03 |
2004-04-15 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
CA2504129A1
(en)
*
|
2002-11-01 |
2004-05-21 |
Promega Corporation |
Cell lysis compositions, methods of use, apparatus, and kit
|
EP1585812B1
(en)
|
2002-12-13 |
2017-01-18 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
ES2630222T3
(es)
*
|
2002-12-13 |
2017-08-18 |
Alphavax, Inc. |
Partículas alfavíricas y métodos de preparación
|
CA2511521C
(en)
|
2002-12-30 |
2012-02-07 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
CA2802143C
(en)
|
2003-01-14 |
2018-06-19 |
Dana-Farber Cancer Institute |
Sparc encoding polynucleotide as a cancer therapy sensitizer
|
MXPA05010007A
(es)
*
|
2003-03-20 |
2006-03-10 |
Alphavax Inc |
Replicones de alfavirus y construcciones auxiliares mejorados.
|
DE602004008451T2
(de)
*
|
2003-05-01 |
2008-05-15 |
Dsm Ip Assets B.V. |
Verfahren zur herstellung von biologischen substanzen durch perfusionskultivierung von suspendierten tierischen zellen
|
US20040229335A1
(en)
*
|
2003-05-15 |
2004-11-18 |
Introgen Therapeutics, Inc. |
Methods and compositions for the production of adenoviral vectors
|
EP1633321A4
(en)
*
|
2003-06-18 |
2006-11-02 |
Onyx Pharma Inc |
METHOD FOR CLEANING VIRUS
|
EP1651666B1
(en)
*
|
2003-07-11 |
2009-05-27 |
Alphavax, Inc. |
Alphavirus-based cytomegalovirus vaccines
|
ATE500267T1
(de)
|
2003-07-21 |
2011-03-15 |
Transgene Sa |
Multifunktionelle cytokine
|
EP1697534B1
(en)
|
2003-12-01 |
2010-06-02 |
Life Technologies Corporation |
Nucleic acid molecules containing recombination sites and methods of using the same
|
JP2007515172A
(ja)
*
|
2003-12-23 |
2007-06-14 |
シェーリング コーポレイション |
無血清培地懸濁培養において安定なa549細胞株を生成するための方法
|
NZ548495A
(en)
*
|
2004-02-23 |
2009-05-31 |
Crucell Holland Bv |
Virus purification methods
|
CN100333797C
(zh)
*
|
2005-01-26 |
2007-08-29 |
彭朝晖 |
重组腺病毒p53制品在肿瘤治疗中的新用途
|
RU2006139258A
(ru)
*
|
2004-04-08 |
2008-05-20 |
Таргеджен, Инк. (US) |
Бензотриазиновые ингибиторы киназ
|
PT1751289E
(pt)
*
|
2004-05-18 |
2009-03-31 |
Alphavax Inc |
Vectores de alfavirais derivados da tc-83, partículas e métodos
|
ES2647477T3
(es)
*
|
2004-06-01 |
2017-12-21 |
Genzyme Corporation |
Composiciones y métodos para prevenir la agregación del vector AAV
|
US20050287616A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Gross Adam F |
Method of assaying denaturation of proteins
|
AU2005276974B2
(en)
|
2004-08-25 |
2012-08-02 |
Targegen, Inc. |
Heterocyclic compounds and methods of use
|
DE202004014949U1
(de)
*
|
2004-09-25 |
2004-11-18 |
Techno-Grafica Gmbh |
Vorrichtung zum Wärmebehandeln einer Beschichtung von Flachoffset-Druckplatten
|
DE102004049290A1
(de)
*
|
2004-10-09 |
2006-04-20 |
Bayer Healthcare Ag |
Verfahren zur Herstellung von Virusmaterial
|
US7901921B2
(en)
|
2004-10-22 |
2011-03-08 |
Oncolytics Biotech Inc. |
Viral purification methods
|
KR20070104339A
(ko)
*
|
2004-11-03 |
2007-10-25 |
인트로겐 테라페티스, 인코퍼레이티드 |
아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
|
CN100497640C
(zh)
*
|
2004-11-26 |
2009-06-10 |
中国人民解放军军事医学科学院生物工程研究所 |
一种高效生产重组腺病毒载体的方法
|
US20060166364A1
(en)
*
|
2004-12-22 |
2006-07-27 |
Introgen, Inc. |
Use of flexible bag containers for viral production
|
US7670837B2
(en)
*
|
2004-12-23 |
2010-03-02 |
Medimmune, Llc |
Non-tumorigenic MDCK cell line for propagating viruses
|
US20060205080A1
(en)
*
|
2005-03-01 |
2006-09-14 |
David Frey |
Formulations for therapeutic viruses having enhanced storage stability
|
SI2567976T1
(sl)
|
2005-03-23 |
2017-11-30 |
Genmab A/S |
Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
|
DK1869171T4
(en)
|
2005-04-11 |
2016-01-18 |
Crucell Holland Bv |
Virus cleaning using ultrafiltration
|
CN101184780B
(zh)
*
|
2005-05-05 |
2012-10-03 |
森馨香料公司 |
β-葡聚糖和甘露聚糖的制备
|
US20060292203A1
(en)
*
|
2005-06-08 |
2006-12-28 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
US20090216452A1
(en)
*
|
2005-07-05 |
2009-08-27 |
Develop Tech Resources |
Energy recovery within a fluid distribution network using geographic information
|
NZ592990A
(en)
*
|
2005-11-01 |
2013-01-25 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
ATE485517T1
(de)
*
|
2006-03-22 |
2010-11-15 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid- targets
|
WO2007127366A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
AU2007347716B2
(en)
*
|
2006-09-15 |
2013-06-20 |
Medimmune, Llc |
MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
|
WO2008092854A2
(en)
|
2007-01-30 |
2008-08-07 |
Transgene S.A. |
Papillomavirus e2 polypeptide used for vaccination
|
US20080299624A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Edward Heslop |
Continuous fermentation apparatus and method
|
ES2588906T3
(es)
*
|
2007-06-21 |
2016-11-07 |
Alphavax, Inc. |
Casetes sin promotor para la expresión de proteínas estructurales de alfavirus
|
HUE024479T2
(en)
*
|
2007-10-08 |
2016-01-28 |
Intrexon Corp |
Genetically altered dendritic cells and uses for cancer treatment
|
ES2399088T3
(es)
|
2007-11-01 |
2013-03-25 |
Perseid Therapeutics Llc |
Polipéptidos y ácidos nucleicos inmunosupresores
|
US20090253184A1
(en)
*
|
2008-01-23 |
2009-10-08 |
Introgen Therapeutics, Inc. |
Compositions and methods related to an adenoviral trans-complementing cell line
|
EP2479287B1
(en)
|
2008-05-13 |
2014-07-23 |
Gen-Probe Incorporated |
Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
|
PL2307551T3
(pl)
*
|
2008-06-18 |
2017-07-31 |
Oxford Biomedica (Uk) Limited |
Oczyszczanie wektorów retrowirusowych
|
CN103952376A
(zh)
|
2008-09-24 |
2014-07-30 |
米迪缪尼有限公司 |
培养细胞、增殖和纯化病毒的方法
|
JP5548207B2
(ja)
*
|
2008-09-24 |
2014-07-16 |
メディミューン,エルエルシー |
ウイルスの精製方法
|
US20110262483A1
(en)
*
|
2008-11-03 |
2011-10-27 |
Ligocyte Pharmaceuticals, Inc. |
Methods for isolating enveloped virus-based vlps free of infectious agents
|
JP5770633B2
(ja)
|
2008-11-03 |
2015-08-26 |
クルセル ホランド ベー ヴェー |
アデノウイルスベクターの産生方法
|
US9523344B2
(en)
*
|
2009-05-26 |
2016-12-20 |
Leviathan Energy Hydroelectric Ltd. |
Hydroelectric in-pipe turbine uses
|
CN103383336A
(zh)
*
|
2009-07-07 |
2013-11-06 |
索尼公司 |
微流体装置
|
WO2011015656A2
(en)
|
2009-08-07 |
2011-02-10 |
Transgene Sa |
Composition for treating hbv infection
|
AU2010305768B2
(en)
|
2009-10-15 |
2015-05-14 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
BR112012008516B1
(pt)
|
2009-10-15 |
2021-10-19 |
Janssen Vaccines & Prevention B.V. |
Método para purificar partículas de adenovírus a partir de uma suspensão de célula
|
AU2011204407B2
(en)
|
2010-01-05 |
2015-05-07 |
Vascular Biogenics Ltd. |
Compositions and methods for treating glioblastoma GBM
|
WO2011083464A2
(en)
|
2010-01-05 |
2011-07-14 |
Vascular Biogenics Ltd. |
Methods for use of a specific anti-angiogenic adenoviral agent
|
SG10201500015TA
(en)
*
|
2010-01-12 |
2015-02-27 |
Vascular Biogenics Ltd |
Methods of producing adenovirus vectors and viral preparations generated thereby
|
AU2011214262B2
(en)
|
2010-02-15 |
2015-05-21 |
Crucell Holland B.V. |
Method for the production of Ad26 adenoviral vectors
|
US9644187B2
(en)
|
2010-04-14 |
2017-05-09 |
Emd Millipore Corporation |
Methods of producing high titer, high purity virus stocks and methods of use thereof
|
CN103052399B
(zh)
|
2010-08-12 |
2016-06-29 |
依生生物制药控股有限公司 |
用于减少病毒组合物中dna杂质的方法
|
AP3390A
(en)
|
2010-09-20 |
2015-08-31 |
Crucell Holland Bv |
Therapeutic vaccination against active tuberculosis
|
CA2809463C
(en)
|
2010-09-27 |
2021-05-25 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
US8892184B2
(en)
|
2010-10-18 |
2014-11-18 |
Siemens Medical Solutions Usa, Inc. |
Systems and methods for reducing interference in a dual modality imaging system
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
EP2461162A1
(en)
|
2010-12-03 |
2012-06-06 |
Texcell, . |
Method for determining the titre of viruses by using infectious standards
|
CN105821078A
(zh)
|
2010-12-09 |
2016-08-03 |
巴斯德研究所 |
用于获得高产量重组蛋白表达的基于mgmt的方法
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Hbv聚合酶突變體
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
TW201321016A
(zh)
|
2011-09-29 |
2013-06-01 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(二)
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
SI2825640T1
(sl)
|
2012-03-12 |
2016-08-31 |
Crucell Holland B.V. |
Šarže rekombinantnega adenovirusa s spremenjenimi konci
|
CN104334188B
(zh)
|
2012-03-22 |
2016-08-24 |
克鲁塞尔荷兰公司 |
抗rsv疫苗
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
CA2878898C
(en)
*
|
2012-07-26 |
2023-01-17 |
Vectalys |
Method for detecting or measuring the impact of a viral vector composition on eukaryotic cells and biomarkers used thereof
|
WO2014066443A1
(en)
|
2012-10-23 |
2014-05-01 |
Emory University |
Gm-csf and il-4 conjugates, compositions, and methods related thereto
|
PL2988780T3
(pl)
|
2013-04-25 |
2019-06-28 |
Janssen Vaccines & Prevention B.V. |
Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
|
KR20160003078A
(ko)
|
2013-05-03 |
2016-01-08 |
허니웰 인터내셔날 인코포레이티드 |
무연 솔더 접속을 위한 리드 프레임 구조체
|
AP2015008893A0
(en)
|
2013-06-17 |
2015-12-31 |
Crucell Holland Bv |
Stabilized soluble pre-fusion rsv f polypeptides
|
US9956166B2
(en)
|
2013-09-18 |
2018-05-01 |
Sorrento Therapeutics, Inc. |
Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
|
JP6466437B2
(ja)
*
|
2013-10-30 |
2019-02-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
微生物を複雑な試料から単離する方法
|
KR20160121562A
(ko)
|
2014-02-20 |
2016-10-19 |
허니웰 인터내셔날 인코포레이티드 |
무연 솔더 조성물
|
EP3613841B1
(en)
|
2014-03-25 |
2022-04-20 |
Terumo BCT, Inc. |
Passive replacement of media
|
ES2750661T3
(es)
|
2014-04-25 |
2020-03-26 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
CN105316296A
(zh)
*
|
2014-06-13 |
2016-02-10 |
亚宝药业太原制药有限公司 |
一种纯化腺病毒颗粒的方法
|
EP3191507A1
(en)
|
2014-09-09 |
2017-07-19 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
GB201417042D0
(en)
*
|
2014-09-29 |
2014-11-12 |
Fkd Therapies Oy |
Method
|
WO2016073693A2
(en)
|
2014-11-05 |
2016-05-12 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
US10597660B2
(en)
|
2014-11-14 |
2020-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
EP3245218A4
(en)
|
2015-01-13 |
2018-10-03 |
Alfa Wassermann, Inc. |
Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
WO2017004592A1
(en)
|
2015-07-02 |
2017-01-05 |
Terumo Bct, Inc. |
Cell growth with mechanical stimuli
|
JP6840718B2
(ja)
|
2015-07-07 |
2021-03-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsv fポリペプチド
|
EA039065B1
(ru)
|
2015-07-07 |
2021-11-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцина против rsv
|
US9663766B2
(en)
*
|
2015-07-24 |
2017-05-30 |
Bio-Rad Laboratories, Inc. |
Methods for purifying adenovirus vectors
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
ES2858315T3
(es)
|
2016-04-05 |
2021-09-30 |
Janssen Vaccines & Prevention Bv |
Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
|
PE20190433A1
(es)
|
2016-04-05 |
2019-03-21 |
Janssen Vaccines And Prevention B V |
Vacuna contra vrs
|
KR102535013B1
(ko)
*
|
2016-04-14 |
2023-05-22 |
트리젤 엘티디. |
정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
|
US11261416B2
(en)
*
|
2016-04-14 |
2022-03-01 |
Trizell Ltd. |
Fixed-bed bioreactor with constant-flow pump / tubing system
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3452081A1
(en)
|
2016-05-04 |
2019-03-13 |
Transgene SA |
Combination therapy with cpg tlr9 ligand
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
EP3458589A4
(en)
|
2016-05-18 |
2020-01-01 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
|
US11965175B2
(en)
|
2016-05-25 |
2024-04-23 |
Terumo Bct, Inc. |
Cell expansion
|
IL264119B2
(en)
|
2016-05-30 |
2023-04-01 |
Janssen Vaccines Prevention B V |
f proteins of rsv are stabilized before fusion
|
US11104874B2
(en)
|
2016-06-07 |
2021-08-31 |
Terumo Bct, Inc. |
Coating a bioreactor
|
US11685883B2
(en)
|
2016-06-07 |
2023-06-27 |
Terumo Bct, Inc. |
Methods and systems for coating a cell growth surface
|
MX2018015540A
(es)
|
2016-06-20 |
2019-04-11 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado.
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Hpvワクチン
|
CN110650673B
(zh)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
US20180119141A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
CN108085301B
(zh)
*
|
2016-11-22 |
2021-10-26 |
贺道耀 |
从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
|
US10294452B2
(en)
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
US20210405031A1
(en)
*
|
2016-12-08 |
2021-12-30 |
Temple University - Of The Commonwealth System Of Higher Education |
Small animal models for in vivo testing of polyomavirus therapeutics
|
WO2018148246A1
(en)
|
2017-02-07 |
2018-08-16 |
Massachusetts Institute Of Technology |
Methods and compositions for rna-guided genetic circuits
|
US11702634B2
(en)
|
2017-03-31 |
2023-07-18 |
Terumo Bct, Inc. |
Expanding cells in a bioreactor
|
US11603542B2
(en)
|
2017-05-05 |
2023-03-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
ハンチントン病治療組成物および方法
|
JP2020519663A
(ja)
|
2017-05-17 |
2020-07-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
Rsv感染に対する防御免疫を誘導するための方法及び組成物
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
EP3654860A1
(en)
|
2017-07-17 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
CN107384873A
(zh)
*
|
2017-09-05 |
2017-11-24 |
成都汇宇生物技术有限公司 |
重组腺病毒的纯化方法
|
AU2018333566A1
(en)
|
2017-09-15 |
2020-02-27 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against RSV
|
AU2018352236A1
(en)
|
2017-10-16 |
2020-04-23 |
The Curators Of The University Of Missouri |
Treatment of amyotrophic lateral sclerosis (ALS)
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
AU2018363202A1
(en)
*
|
2017-11-08 |
2020-05-21 |
Blue Sky Vaccines Gmbh |
SO3 chromatography for use in a method for virus purification
|
EP3762500A1
(en)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒(aav)之組成物和方法
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
パーキンソン病を治療するための組成物および方法
|
EP3793615A2
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Directed evolution of aav to improve tropism for cns
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
EP3818161A1
(en)
|
2018-07-02 |
2021-05-12 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
KR20220036908A
(ko)
|
2018-08-28 |
2022-03-23 |
보르 바이오파마 인크. |
유전자 조작된 조혈 줄기 세포 및 그의 용도
|
AU2019354995A1
(en)
|
2018-10-02 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
WO2020123524A1
(en)
*
|
2018-12-11 |
2020-06-18 |
Erbi Biosystems, Inc. |
Methods of manufacturing cell based products using small volume perfusion processes
|
TW202039858A
(zh)
|
2019-01-18 |
2020-11-01 |
美商航海家醫療公司 |
用於生產aav顆粒之方法及系統
|
EP3927833A4
(en)
|
2019-02-21 |
2022-11-30 |
Unleash Immuno Oncolytics, Inc. |
ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
|
CN110093455B
(zh)
*
|
2019-04-27 |
2020-03-17 |
中国医学科学院病原生物学研究所 |
一种呼吸道病毒的检测方法
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
CN112175996A
(zh)
*
|
2019-07-05 |
2021-01-05 |
杭州荣泽生物科技有限公司 |
一种基因治疗载体的制备方法和用途
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
US20220364114A1
(en)
|
2019-08-26 |
2022-11-17 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
US11981885B2
(en)
*
|
2019-11-15 |
2024-05-14 |
City Of Hope |
System, device and method for production of bioproduct including high density cell respirator (HDCR) for intensified production of adeno-associated viruses (AAV) and cell-based production
|
CN110894494B
(zh)
*
|
2019-11-22 |
2022-09-27 |
广西梧州制药(集团)股份有限公司 |
一种大规模高密度悬浮培养293细胞高产腺病毒的方法
|
US20230131352A1
(en)
|
2020-04-01 |
2023-04-27 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
CN116249712A
(zh)
|
2020-04-15 |
2023-06-09 |
沃雅戈治疗公司 |
Tau结合化合物
|
GB202005732D0
(en)
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
CN112226418B
(zh)
*
|
2020-09-25 |
2022-07-08 |
阜外华中心血管病医院 |
重组腺相关病毒纯化方法
|
US20230374542A1
(en)
|
2020-10-07 |
2023-11-23 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
|
CN112293394B
(zh)
*
|
2020-10-30 |
2022-11-25 |
海南德安欣有害生物防治科技有限公司 |
一种捕鼠装置及捕鼠方法
|
CA3196778A1
(en)
|
2020-11-02 |
2022-05-05 |
Biomarin Pharmaceutical, Inc. |
Process for enriching adeno-associated virus
|
GB202019454D0
(en)
*
|
2020-12-10 |
2021-01-27 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Method for purifying virus
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2022221529A1
(en)
|
2021-04-16 |
2022-10-20 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
WO2023034990A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034997A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034989A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034996A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034980A1
(en)
|
2021-09-03 |
2023-03-09 |
Bomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034994A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
AU2022349103A1
(en)
|
2021-09-27 |
2024-03-28 |
Sotio Biotech Inc. |
Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
|
WO2023081648A1
(en)
|
2021-11-02 |
2023-05-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
CA3237201A1
(en)
|
2021-11-16 |
2023-05-25 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
TW202334181A
(zh)
|
2021-11-17 |
2023-09-01 |
美商航海家醫療公司 |
Aav蛋白殼變異體及其用途
|
WO2023111580A1
(en)
|
2021-12-16 |
2023-06-22 |
University Of Dundee |
Targeted degradation of alpha-synuclein
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
GB202201713D0
(en)
|
2022-02-10 |
2022-03-30 |
Univ Dundee |
An affinity directed phosphatase system for targeted protein dephosphorylation
|
CN115354033A
(zh)
*
|
2022-03-25 |
2022-11-18 |
上海碧博生物医药科技有限公司 |
一种细胞裂解液、细胞裂解方法及该方法在收获aav的应用
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
CN117551624A
(zh)
*
|
2024-01-11 |
2024-02-13 |
深圳源兴基因技术有限公司 |
一种基于无血清悬浮扩增的高效回收腺病毒的方法
|